qPSMA:基于68Ga-PSMA11 PET/CT的前列腺癌全身肿瘤负荷半自动评估软件
研究介绍并验证了qPSMA软件,用于前列腺癌患者68Ga-PSMA11 PET/CT全身肿瘤负荷的半自动评估。PSMA-TV和PSMA-TL与血清PSA显著相关(r=0.72, P<0.001;r=0.66, P=0.002)。
要点
- qPSMA可半自动分割骨和软组织病灶,输出PSMA-TV、PSMA-TL、SUVmean和SUVmax。
- 自动肝脏本底计算与METAVOL平均相对差异0.74%,ICC为0.996。
- 与Syngo.via比较,PSMA-TV、PSMA-TL、SUVmean和SUVmax的ICC分别为1.000、1.000、0.995和0.999。
核心结论
- qPSMA是稳健的软件包,可帮助医生量化重度转移性前列腺癌患者的肿瘤负荷。
研究设计与样本
- 进行四项分析:肝脏本底活动测定验证、观察者内和观察者间变异性评估、与Syngo.via比较验证、计算时间评估及PSMA PET衍生参数与血清PSA比较。
主要发现
- 自动肝脏本底计算与METAVOL相比平均相对差异为0.74%(ICC 0.996;95%CI 0.989;0.998)。
- 观察者内和观察者间变异性分析显示高度一致性(所有ICC均>0.990)。
- 68个病灶的定量输出参数在qPSMA与Syngo.via之间配对t检验无显著差异。
- PSMA-TV、PSMA-TL、SUVmean和SUVmax的ICC分别为1.000(95%CI 1.000;1.000)、1.000(95%CI 1.000;1.000)、0.995(95%CI 0.992;0.997)和0.999(95%CI 0.999;1.000)。
- 观察者内变异性第一次和第二次读取的平均计算时间分别为13.63分钟(范围8.22-25.45分钟)和9.27分钟(范围8.10-12.15分钟)(P=0.001)。
关键数值与推荐
- 骨病灶分割使用基于CT的骨掩模,软组织病灶分割使用SUV阈值3和基于肝脏的阈值。
- 输出参数包括PSMA-TV、PSMA-TL、PSMA SUVmean和PSMA SUVmax。
临床怎么用
- qPSMA可用于68Ga-PSMA11 PET/CT全身肿瘤负荷的半自动分析,辅助量化重度转移性前列腺癌患者的肿瘤负荷。
局限性
- 研究未报告软件对不同扫描仪或不同PSMA配体的泛化性验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Our aim was to introduce and validate qPSMA, a semiautomatic software package for whole-body tumor burden assessment in prostate cancer patients using 68Ga-prostate-specific membrane antigen (PSMA) 11 PET/CT. Methods: qPSMA reads hybrid PET/CT images in DICOM format. Its pipeline was written using Python and C++ languages. A bone mask based on CT and a normal-uptake mask including organs with physiologic 68Ga-PSMA11 uptake are automatically computed. An SUV threshold of 3 and a liver-based threshold are used to segment bone and soft-tissue lesions, respectively. Manual corrections can be applied using different tools. Multiple output parameters are computed, that is, PSMA ligand-positive tumor volume (PSMA-TV), PSMA ligand-positive total lesion (PSMA-TL), PSMA SUVmean, and PSMA SUVmax Twenty 68Ga-PSMA11 PET/CT data sets were used to validate and evaluate the performance characteristics of qPSMA. Four analyses were performed: validation of the semiautomatic algorithm for liver background activity determination, assessment of intra- and interobserver variability, validation of data from qPSMA by comparison with Syngo.via, and assessment of computational time and comparison of PSMA PET-derived parameters with serum prostate-specific antigen. Results: Automatic liver background calculation resulted in a mean relative difference of 0.74% (intraclass correlation coefficient [ICC], 0.996; 95%CI, 0.989;0.998) compared with METAVOL. Intra- and interobserver variability analyses showed high agreement (all ICCs > 0.990). Quantitative output parameters were compared for 68 lesions. Paired t testing showed no significant differences between the values obtained with the 2 software packages. The ICC estimates obtained for PSMA-TV, PSMA-TL, SUVmean, and SUVmax were 1.000 (95%CI, 1.000;1.000), 1.000 (95%CI, 1.000;1.000), 0.995 (95%CI, 0.992;0.997), and 0.999 (95%CI, 0.999;1.000), respectively. The first and second reads for intraobserver variability resulted in mean computational times of 13.63 min (range, 8.22-25.45 min) and 9.27 min (range, 8.10-12.15 min), respectively (P = 0.001). Highly significant correlations were found between serum prostate-specific antigen value and both PSMA-TV (r = 0.72, P < 0.001) and PSMA-TL (r = 0.66, P = 0.002). Conclusion: Semiautomatic analyses of whole-body tumor burden in 68Ga-PSMA11 PET/CT is feasible. qPSMA is a robust software package that can help physicians quantify tumor load in heavily metastasized prostate cancer patients.
引用
- Gafita A, Bieth M, Krönke M, et al. qPSMA: Semiautomatic Software for Whole-Body Tumor Burden Assessment in Prostate Cancer Using 68Ga-PSMA11 PET/CT. J Nucl Med. 2019. PMID: 30850484. doi:10.2967/jnumed.118.224055
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。